Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Notes Payables: 2022-2023

Supernus Pharmaceuticals' Notes Payables was N/A to $402.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $402.5 million, marking a year-over-year change of. This contributed to the annual value of $402.0 million for FY2022, which is N/A change from last year.
As of Q1 2023, Supernus Pharmaceuticals' Notes Payables stood at $402.5 million, which was up 0.13% from $402.0 million recorded in Q4 2022.
Supernus Pharmaceuticals' 5-year Notes Payables high stood at $402.5 million for Q1 2023, and its period low was $402.0 million during Q4 2022.
Over the past 2 years, Supernus Pharmaceuticals' median Notes Payables value was $402.2 million (recorded in 2022), while the average stood at $402.2 million.